nodes	percent_of_prediction	percent_of_DWPC	metapath
Diphenhydramine—SLC22A2—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.0548	0.0863	CbGpPWpGaD
Diphenhydramine—SLC22A1—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.0511	0.0805	CbGpPWpGaD
Diphenhydramine—Captodiame—DRD3—Gilles de la Tourette syndrome	0.0474	0.13	CrCbGaD
Diphenhydramine—Diphenylpyraline—SLC6A3—Gilles de la Tourette syndrome	0.0342	0.0937	CrCbGaD
Diphenhydramine—SLC22A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.0274	0.0432	CbGpPWpGaD
Diphenhydramine—Benzatropine—SLC6A3—Gilles de la Tourette syndrome	0.0262	0.0719	CrCbGaD
Diphenhydramine—SLC22A1—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.0256	0.0403	CbGpPWpGaD
Diphenhydramine—Chlorphenamine—SLC6A3—Gilles de la Tourette syndrome	0.0199	0.0545	CrCbGaD
Diphenhydramine—HRH1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0195	0.0307	CbGpPWpGaD
Diphenhydramine—Modafinil—SLC6A3—Gilles de la Tourette syndrome	0.0194	0.0532	CrCbGaD
Diphenhydramine—CHRM2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0192	0.0302	CbGpPWpGaD
Diphenhydramine—SLC22A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.019	0.03	CbGpPWpGaD
Diphenhydramine—SLC22A1—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.0177	0.028	CbGpPWpGaD
Diphenhydramine—Benzphetamine—SLC6A3—Gilles de la Tourette syndrome	0.0168	0.0461	CrCbGaD
Diphenhydramine—Atomoxetine—SLC6A3—Gilles de la Tourette syndrome	0.0167	0.0458	CrCbGaD
Diphenhydramine—HRH1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0166	0.0262	CbGpPWpGaD
Diphenhydramine—Cyclobenzaprine—HTR2A—Gilles de la Tourette syndrome	0.0163	0.0448	CrCbGaD
Diphenhydramine—CHRM2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0163	0.0257	CbGpPWpGaD
Diphenhydramine—HRH1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0161	0.0254	CbGpPWpGaD
Diphenhydramine—CHRM2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0159	0.025	CbGpPWpGaD
Diphenhydramine—HRH1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.015	0.0237	CbGpPWpGaD
Diphenhydramine—CHRM2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0148	0.0233	CbGpPWpGaD
Diphenhydramine—Promazine—DRD4—Gilles de la Tourette syndrome	0.0145	0.0397	CrCbGaD
Diphenhydramine—Cinnarizine—DRD2—Gilles de la Tourette syndrome	0.014	0.0383	CrCbGaD
Diphenhydramine—HRH1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.014	0.022	CbGpPWpGaD
Diphenhydramine—Trimipramine—SLC6A3—Gilles de la Tourette syndrome	0.0137	0.0376	CrCbGaD
Diphenhydramine—CHRM2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0137	0.0216	CbGpPWpGaD
Diphenhydramine—HRH1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0136	0.0214	CbGpPWpGaD
Diphenhydramine—CHRM2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0133	0.021	CbGpPWpGaD
Diphenhydramine—HRH1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0126	0.0199	CbGpPWpGaD
Diphenhydramine—CHRM2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0124	0.0196	CbGpPWpGaD
Diphenhydramine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.0118	0.0186	CbGpPWpGaD
Diphenhydramine—Amitriptyline—DRD3—Gilles de la Tourette syndrome	0.0109	0.0298	CrCbGaD
Diphenhydramine—HRH1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0105	0.0166	CbGpPWpGaD
Diphenhydramine—CHRM2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0104	0.0163	CbGpPWpGaD
Diphenhydramine—Trimipramine—DRD2—Gilles de la Tourette syndrome	0.0102	0.028	CrCbGaD
Diphenhydramine—Imipramine—SLC6A3—Gilles de la Tourette syndrome	0.0102	0.0279	CrCbGaD
Diphenhydramine—Promethazine—DRD2—Gilles de la Tourette syndrome	0.00984	0.027	CrCbGaD
Diphenhydramine—Doxepin—DRD2—Gilles de la Tourette syndrome	0.00974	0.0267	CrCbGaD
Diphenhydramine—Atomoxetine—HTR2A—Gilles de la Tourette syndrome	0.0096	0.0263	CrCbGaD
Diphenhydramine—HRH1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00884	0.0139	CbGpPWpGaD
Diphenhydramine—CHRM2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0087	0.0137	CbGpPWpGaD
Diphenhydramine—Promazine—DRD2—Gilles de la Tourette syndrome	0.00866	0.0237	CrCbGaD
Diphenhydramine—Trimipramine—HTR2A—Gilles de la Tourette syndrome	0.0079	0.0216	CrCbGaD
Diphenhydramine—Promethazine—HTR2A—Gilles de la Tourette syndrome	0.00761	0.0208	CrCbGaD
Diphenhydramine—Imipramine—DRD2—Gilles de la Tourette syndrome	0.00758	0.0208	CrCbGaD
Diphenhydramine—Amitriptyline—DRD2—Gilles de la Tourette syndrome	0.00753	0.0206	CrCbGaD
Diphenhydramine—Doxepin—HTR2A—Gilles de la Tourette syndrome	0.00753	0.0206	CrCbGaD
Diphenhydramine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00745	0.0117	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00726	0.0114	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00705	0.0111	CbGpPWpGaD
Diphenhydramine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00694	0.0109	CbGpPWpGaD
Diphenhydramine—Promazine—HTR2A—Gilles de la Tourette syndrome	0.00669	0.0183	CrCbGaD
Diphenhydramine—Imipramine—HTR2A—Gilles de la Tourette syndrome	0.00586	0.016	CrCbGaD
Diphenhydramine—Amitriptyline—HTR2A—Gilles de la Tourette syndrome	0.00582	0.0159	CrCbGaD
Diphenhydramine—SLC22A5—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00538	0.00847	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.0046	0.00724	CbGpPWpGaD
Diphenhydramine—SLC22A2—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00417	0.00657	CbGpPWpGaD
Diphenhydramine—SLC22A1—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00389	0.00613	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—HDC—Gilles de la Tourette syndrome	0.00349	0.00549	CbGpPWpGaD
Diphenhydramine—CHRM2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.0034	0.00535	CbGpPWpGaD
Diphenhydramine—SLC22A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00338	0.00533	CbGpPWpGaD
Diphenhydramine—CHRM2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.0033	0.0052	CbGpPWpGaD
Diphenhydramine—HRH1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00321	0.00505	CbGpPWpGaD
Diphenhydramine—SLC22A2—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.0032	0.00504	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00315	0.00497	CbGpPWpGaD
Diphenhydramine—SLC22A1—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00315	0.00497	CbGpPWpGaD
Diphenhydramine—HRH1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00311	0.0049	CbGpPWpGaD
Diphenhydramine—CHRM2—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00307	0.00484	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00306	0.00482	CbGpPWpGaD
Diphenhydramine—CHRM2—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00299	0.00471	CbGpPWpGaD
Diphenhydramine—SLC22A1—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00298	0.0047	CbGpPWpGaD
Diphenhydramine—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.0029	0.00457	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00285	0.00449	CbGpPWpGaD
Diphenhydramine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00275	0.00433	CbGpPWpGaD
Diphenhydramine—SLC22A5—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.00273	0.0043	CbGpPWpGaD
Diphenhydramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.0027	0.00426	CbGpPWpGaD
Diphenhydramine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00267	0.0042	CbGpPWpGaD
Diphenhydramine—HRH1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00263	0.00414	CbGpPWpGaD
Diphenhydramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00262	0.00413	CbGpPWpGaD
Diphenhydramine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00248	0.00391	CbGpPWpGaD
Diphenhydramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00244	0.00385	CbGpPWpGaD
Diphenhydramine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00235	0.0037	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—HDC—Gilles de la Tourette syndrome	0.00231	0.00365	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—HDC—Gilles de la Tourette syndrome	0.00225	0.00354	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—HDC—Gilles de la Tourette syndrome	0.00216	0.0034	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00209	0.00329	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00206	0.00324	CbGpPWpGaD
Diphenhydramine—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00203	0.0032	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00203	0.0032	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.002	0.00315	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.002	0.00315	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00189	0.00298	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00186	0.00293	CbGpPWpGaD
Diphenhydramine—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00174	0.00274	CbGpPWpGaD
Diphenhydramine—SLC22A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.00172	0.00271	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—HDC—Gilles de la Tourette syndrome	0.00171	0.0027	CbGpPWpGaD
Diphenhydramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00171	0.0027	CbGpPWpGaD
Diphenhydramine—SLC22A1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.0016	0.00252	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00132	0.00209	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.0013	0.00205	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—HDC—Gilles de la Tourette syndrome	0.0013	0.00204	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	0.00119	0.00188	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00118	0.00186	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—HDC—Gilles de la Tourette syndrome	0.00118	0.00186	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00116	0.00183	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00115	0.00181	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00113	0.00178	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00107	0.00169	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00107	0.00168	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00106	0.00166	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00105	0.00166	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00104	0.00164	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00103	0.00161	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—HDC—Gilles de la Tourette syndrome	0.00101	0.00159	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000971	0.00153	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000955	0.0015	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000749	0.00118	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000737	0.00116	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00068	0.00107	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000669	0.00105	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000634	0.000999	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000624	0.000983	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000615	0.00097	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000606	0.000954	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000573	0.000903	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000564	0.000889	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000402	0.000633	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000395	0.000622	CbGpPWpGaD
